The following post is one of a series of posts appearing Monday through Friday on The Cancer Blog. This feature -- Today, I am grateful -- allows me to share with readers my appreciation for all the treasures in my life, both big and small. In my post-cancer world, I find It healing for my soul to be mindful of the good in my life. It is my pleasure to share my gratitude with you.

The night before my lumpectomy, way back in December 2005, I was consumed with fear, worry, and panic. Since I'd found it, the lump in my left breast had been sitting untouched for nearly two weeks. I imagined the mass spreading with each day and believed I could detect its growth each time I felt for it. A doctor told me if it was growing like I thought it was, my tiny pea-sized tumor would be the size of an apple within days.

My fears were unfounded and irrational. I know that now. But during the moments of uncertainty that filled my days between diagnosis and prognosis, I had no direction. I had only my wandering mind for company. The waiting really is the hardest part. Once faced with the specifics of our diseases, we can take action.

Researchers are reporting that a new vaccine designed to treat breast cancer appears to be safe in women with advanced disease. It showed signs of slowing down tumor growth too.

The Neuvenge vaccine, made by Dendreon Corporation -- maker of the Provenge prostate cancer vaccine -- targets the aggressive Her-2 positive form of breast cancer, which affects 20 to 30 percent of breast cancer patients. Using immune cells from a cancer patient's own body, Neuvenge is a tailor-made therapy.

Reports about Neuvenge, published in the Journal of Clinical Oncology, indicate the vaccine did not cause any serious side effects and of the 18 women who participated in the Phase I study, there was a reduction in the size of a tumor in one patient. In three other women, the disease seemed to stabilize for as long as a year.

My sister has skin cancer -- the basal cell variety. She has two spots, both on her chest, each one scheduled to be surgically removed in a few weeks. If it were me with this new diagnosis, I'm sure I'd be freaking out, maybe because I've already had breast cancer and tend to panic about any cancer or maybe just because I'm a worrier by nature. But my sister is taking her cancer news in stride, and I am too -- because now that I've done a little research, it seems this type of cancer is pretty easy to beat.

Here's a little refresher lesson on the skin: The skin is the largest organ in the body, and is made of three layers -- the epidermis (top layer), dermis (middle layer), and subcutis (deepest layer). For the purpose of this post, let's focus on the epidermis.

The epidermis has three layers -- an upper, middle, and a bottom layer. This bottom layer is comprised of basal cells. This is where basal cell cancer begins.

A man who was told he was dying of cancer has been eluding police and the courtroom in New Zealand to avoid going to prison. His reasoning? Since he's dying, he's got nothing to lose and he doesn't want to spend his final days in prison. To be honest, I don't blame him. I might do the same thing if I was staring death in the face.

But now officials are beginning to question the legitimacy of his cancer claims. A known methamphetamine addict, 34-year-old Tifiga Atanoa was arrested with a large tumor on his neck, but that has since seemingly disappeared. What's more, upon re-arrest, he didn't admit to any illness. Is he ill or a liar looking for an excuse to run from the law? He's in police custody now and will face trial later this month.

The folks at Canyon Ranch in Tucson, Arizona told me all about the merits of flax seed. They told me to sprinkle it here, sprinkle it there, sprinkle it everywhere. While at this desert destination, I did just that. I dipped into the bowls of flax scattered at all dining locations, and I topped my bagels, cereals, salads, and more with this powerful substance. As soon as I got home from this little slice of paradise, I bought my own personal container of flax. I promptly placed it in my refrigerator, have used it a few times, and just recently realized I'd forgotten why exactly it's so good for me.

I've done some research, and now I know a little more about this thing called flax -- and I remember why it must become a part of my everyday life.

Flax, also known as Common Flax or Linseed, is an annual plant that grows to 120 cm tall, with slender stems. Native to the region extending from the eastern Mediterranean to India, its leaves are green, its flowers blue, its fruit round and containing glossy brown seeds. Grown for both its seeds and its fibers, parts of this plant are used to make fabric, dye, paper, medicines, fishing nets, and soap. The seeds, like what sit in my refrigerator, come in two forms -- brown and yellow or golden. The yellow, golden variety is the one most often consumed.

Tykerb (lapatinib) may be effective at shrinking breast cancer tumors in the brain, researchers say. This drug is called a targeted therapy because it can kill cancer cells and leave normal cells alone. Tykerb targets HER2 and EGFR, two proteins that function abnormally in breast cancer cells.

A study was conducted that included 241 breast cancer patients with brain metastasis that continued to progress after radiation treatment and Herceptin therapy.

The study concluded that nearly half of the patients, 46 percent, experienced at least a twenty percent reduction in the size the the brain tumors.

The researchers concluded "Tykerb has promise in the treatment of brain metastasis".

Glioblastoma Multiforme (GBM), also known as a grade IV astrocytoma, is the most common and most aggressive type of primary brain tumor. Although GBM can occur at any age, the disease is most commonly diagnosed after the age of 50.

I wanted to discuss this type of cancer and add it to the Cancer by the Numbers feature because it has directly affected my family. My 39-year-old uncle died of the disease in 1987. He only survived a year after diagnosis. It is disheartening that this disease has not seen any strides in improved survival rates over all these years.

The Numbers

GBM accounts for 52 percent of all primary brain tumor cases. Brain tumors account for one in every 100 cancers diagnosed annually in the United States. Most malignant brain tumors and brain cancers have spread from other tumors in the body to the skull, including cancers of the breast and lung, malignant melanoma and blood cell cancers.

Melanoma that has spread to other areas of the body is a very difficult cancer to treat successfully. It usually does not respond well to chemotherapy. Sadly, those diagnosed with metastatic melanoma survive only about a year after diagnosis.

The combination of Taxol (paclitaxel) with carboplatin, added to an agent that prevents the growth of blood vessels called bevacizumab has been shown to significantly delay the spread of tumors in patients with advanced melanoma. A Phase II clinical trial showed that tumor growth was delayed by almost six months; typically these cancers begin to start spreading again in about eight weeks.

Dr. Domingo Perez, M.D., the lead author of the study says "The clinical benefit may seem small, but in the world of melanoma where there is very little progress, this is certainly a strong indication that the combination of chemotherapy with an antiangiogenic agent may be a valid treatment strategy for these patients."

New cancer drug Torisol was approved on Wednesday by the FDA for use with renal cell carcinoma, an advanced form of kidney cancer.

Torisol, also known as temsirolimus, is an enzyme inhibitor made by Wyeth Pharmaceuticals and has shown promise for prolonging patient survival. It's the third kidney cancer drug approved in the past 18 months -- the other two are Nexavar, intended to delay disease progression, and Sutent, for tumor size reduction.

Many kidney cancer patients are cured by surgery. About 35 percent of patients, however, experience a recurrence or a spread of the disease. Until just recently, there were no effective drugs to control these issues. Now there are several -- and Torisol is the one showing modest improvement in survival for patients with the most advanced tumors. Further study will indicate whether or not the drug is useful for patients with less extensive metastatic disease.

Drugs currently in trials for obesity and diabetes may soon be fast-tracked for use in the fight against breast cancer. Typically, it takes many years to research and develop new drugs. But these already-developed drugs, if successful, could reach the market much quicker.

The drugs, believed to work by blocking the enzyme PTP1B, could help breast cancer patients because the enzyme is found in high levels in about 40 percent of these patients.

Studies on mice show blocking production of the enzyme significantly slowed tumor development. In some cases, it stopped the spread of the cancer and it might even stop some tumors from forming.

It's been suspected that taking too many vitamins may spike men's risk of dying from prostate cancer. On Wednesday, the biggest study yet to link high-dose multivitamins and prostate damage was published in the Journal of the National Cancer Institute.

Government scientists have been looking at the diet and health of almost 300,000 men. One third reported taking a daily multivitamin. Five percent were heavy users, marked by use more than seven times per week. Within five years of the study's launch, 10,241 men had been diagnosed with prostate cancer. About 1,476 had an advanced form of the disease. And 179 died.

It seems heavy multivitamin users were nearly twice as likely to get fatal prostate cancer as men who never took the pills. Yet, oddly, researchers found no link between multivitamin use and early-stage prostate cancer. It could be that vitamins have little effect until a tumor appears -- and then it spurs growth.

More studies are on the horizon for this topic, which is becoming more and more pressing.

UK researchers have developed a 3D laboratory model of human breast cancer, specifically ductal carcinoma in situ (DCIS). The model, complete with normal cells and tumor cells, should help experts understand how the disease develops in its early stages, and it could replace the need for experiments in animals.

About one in five breast cancers in the UK start out as DCIS. Researchers wanted to learn more about how the early cancerous changes in cells develop into larger tumors, and they chose to fashion a 3D test tube model because it is more complex than a layer of cells in a Petri dish.

Once this experiment is proved successful, it could reduce and perhaps replace animal studies.

"With breast cancer, there is an urgent need to move away from animal research models because their similarity to human cancer can be so poor," says one expert who explains this model could help revolutionize breast cancer research -- because unreliable research costs time, money, and lives, both animal and human lives.

The Utah Jazz's Derek Fisher finds himself in a whole new ballgame lately as he helps his 10-month-old daughter, Tatum, fight for her life.

Tatum was diagnosed last week with retinoblastoma, a cancerous tumor in her left eye. Fisher, who was excused from his team to begin dealing with his daughter's illness, flew his family -- his wife Candace, Tatum, and Tatum's twin brother Drew -- to New York on Monday to see a specialist.

Fisher and his wife must decide on a course of treatment for their daughter. Their options are removal of the eye or a combination of surgery and chemotherapy. Their most pressing goal is to save Tatum's life. They also want to save her eye. And they think in her case, she should be able to keep her eye.

New hope may be an injection away for patients living with glioma, a terminal brain cancer that comes with a life expectancy of about 25 weeks post-diagnosis.

A new vaccine called Vitaspen is made by using tissue extracted from each person's cancerous tumor. The tissue is used as a unique footprint for the vaccine that targets destructive tumor tissue while sparing healthy tissue in the same region.

Vitaspen is only in the first stage of clinical human trials, but researchers are pleased with the promise of the new drug -- particularly the benefits trial participants are gaining form the treatment. They have reported no adverse side effects, and the drug has increased the overall survival rate.

Results of stage one trials will determine if the drug warrants stage two testing.

Back in the news: the link between hormone replacement therapy (HRT) and breast cancer. This time, the connection is seemingly more conclusive than before, when some argued that many factors influence the risk of breast cancer, that HRT could not do the job all on its own.

Now, two separate studies offer up powerful evidence that HRT is linked to tumor growth. Case in point: when use of the therapy drops, so do incidences of breast cancer.

New figures in the New England Journal of Medicine suggest there have been 16,000 fewer cases of breast cancer nationwide since mid-2002, when women stopped taking their hormone pills following the federal Women's Health Initiative announcement connecting the therapy with increased risk of breast cancer, stroke, and heart attack.

Many did not want to believe HRT was to blame for so many breast cancer diagnoses. And maybe it's not the actual cause of the disease, but the fuel for tumors trying to grow.

These new findings do not appear to be a statistical fluke, says one doctor. Numbers have been computed and re-computed, and the message is clear: HRT is strongly implicated as the guilty party. There is just no other culprit, says a statistician at the National Cancer Institute.

Wyeth, maker of Premarin and Prempro -- two forms of hormone therapy -- continues to caution women against drawing any conclusions about HRT and breast cancer. There still may be broader explanation for the decline in cases, say their spokespeople.